Date: October 28, 2019
Source: UTop Pharma News Center
At the prestigious APIC Annual Conference (Active Pharmaceutical Ingredients Committee, USA) — one of the world’s most influential gatherings in the API industry — UTop Pharma made its debut as an independent exhibitor, presenting its latest breakthrough in the GLP-1 analog intermediate synthesis and purification process.
This milestone marks UTop Pharma’s official entry into the international high-end peptide API supply chain and reflects the company’s forward-looking vision in the global diabetes and metabolic disease markets.
During the conference, UTop Pharma’s newly developed GLP-1 analog intermediate refinement process captured widespread attention. By integrating multi-dimensional purification pathways with precise process control, the company successfully achieved a total impurity level below 0.1%, setting a new industry benchmark for purity and consistency.
The UTop Pharma booth attracted professional visitors from Europe, the United States, Japan, and India. Many expressed strong interest in potential cooperation on GLP-1 receptor agonist APIs, such as liraglutide and semaglutide.
“We want the global industry to see that China is not just capable of manufacturing — we are capable of innovating.
UTop Pharma aims to become a technology contributor in the global peptide field, not merely a producer.”
— CEO & Founder of UTop Pharma, speaking at the APIC conference
GLP-1 analogs are among the fastest-growing therapeutic peptides worldwide. However, their intermediate synthesis has long been considered a high-barrier, low-yield challenge. Through continuous optimization of reaction kinetics and process parameters, UTop Pharma developed a proprietary high-efficiency coupling system and selective deprotection strategy, significantly improving both yield and purity.
In the purification stage, the company implemented a multi-dimensional gradient HPLC system combined with a high-throughput process verification platform, ensuring batch-to-batch consistency and impurity levels below 0.05%.
Industry experts at the conference recognized this achievement as “a truly competitive peptide intermediate solution from China.”
UTop Pharma’s participation in the APIC conference represents more than a technological showcase — it is a key step in the company’s global expansion.
During the event, UTop Pharma reached preliminary cooperation agreements with several international pharmaceutical companies to co-develop next-generation GLP-1 derivatives and long-acting formulations.
The company also announced plans to strengthen its global regulatory presence by preparing DMF (Drug Master File) submissions for both the U.S. FDA and the European EMA, ensuring full compliance with international pharmaceutical standards.
UTop Pharma believes that being able to present at such a high-profile international conference demonstrates not only technological capability but also growing global influence.
By shifting its focus from manufacturing capacity to standard-setting capability, the company is building a global competitiveness framework centered on quality, consistency, and innovation.
“Through higher standards and open collaboration, we aim to contribute to the global advancement of peptide therapeutics.”
— Director of International Business, UTop Pharma
As GLP-1 analogs continue to reshape the treatment landscape for diabetes and obesity, UTop Pharma is stepping onto the world stage with confidence and purpose.
Through full-chain innovation — from synthesis to purification to standardization — the company has not only achieved technological breakthroughs but also elevated the reputation of China’s peptide industry in the global market.
Guided by the philosophy of “Technology-Driven, Standard-Oriented,” UTop Pharma is committed to transforming China’s peptide manufacturing from “follower” to “global leader.”
Issued by: Technical & International Business Division
Editor: Corporate Communications Department
Date of Publication: October 28, 2019
